Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.76 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758316 | 0.88 | GRIA3 (0.97) | GRIA3GRIA4HPGDSMN1; SMN2POLB | |
| SCHEMBL5760125 | 0.86 | GRIA3 (1.00) | GRIA3GRIA4HPGDSMN1; SMN2POLB | |
| Farampator SCHEMBL677135 | 0.86 | GRIA3 (1.00) | GRIA3GRIA4HPGDSMN1; SMN2POLB | |
| SCHEMBL5791567 | 0.85 | GRIA3 (0.72) | GRIA3GRIA4HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL6575384 | 0.84 | GRIA3 (0.74) | GRIA3GRIA4HPGDPOLBTSHR | |
| SCHEMBL5757878 | 0.84 | GRIA3 (0.74) | GRIA3GRIA4HPGDSMN1; SMN2KMT2A | |
| SCHEMBL5759402 | 0.82 | GRIA3 (0.72) | GRIA3GRIA4HPGDSMN1; SMN2HSP90AA1 | |
| SCHEMBL14028268 | 0.82 | GRIA3 (0.67) | GRIA3GRIA4HPGDSMN1; SMN2KMT2A | |
| SCHEMBL5755898 | 0.81 | GRIA3 (0.70) | GRIA3GRIA4HPGDKMT2APOLB | |
| SCHEMBL243412 | 0.81 | GRIA3 (0.70) | GRIA3GRIA4HPGDKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | claimed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | claimed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | claimed |
| US-20190030041-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | UNIV ALBERTA (CA) | 2019-01-31 | — | — | US | claimed |
| US-20160120873-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | UNIV ALBERTA (CA) | 2016-05-05 | — | — | US | claimed |
| US-20120004219-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-01-05 | — | — | US | claimed |
| US-8039468-B2 | administering to subject having respiratory depression a positive allosteric AMPA receptor modulator; selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-10-18 | — | — | US | claimed |
| EP-2061471-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | The Governors of the University of Alberta (CA) | 2009-05-27 | — | — | EP | claimed |
| US-20080261962-A1 | administering to subject having respiratory depression a positive allosteric AMPA receptor modulator; selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2008-10-23 | — | — | US | claimed |
| WO-2008025148-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2008-03-06 | — | — | WO | claimed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | claimed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | claimed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2025-07-29 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250114464-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | UNIV ALBERTA (CA) | 2025-04-10 | — | — | US | disclosed |
| US-20250064823-A1 | THIADIAZINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2025-02-27 | — | — | US | disclosed |
| US-20250051323-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2025-02-13 | — | — | US | disclosed |
| US-12194050-B2 | Thiadiazine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-01-14 | — | — | US | disclosed |
| CN-112119076-B | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | US | disclosed |
| CN-119137274-A | Peptide conjugated antisense therapeutics for the treatment of diseases that modulate pre-mRNA splicing | 阿尔伯塔大学理事会 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469576-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | The Governors of the University of Alberta (CA) | 2024-12-04 | — | — | EP | disclosed |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | UNIV CASE WESTERN RESERVE (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024211430-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3873467-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12064410-B2 | Compositions and methods for stimulating ventilatory and/or respiratory | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| CN-112823157-B | Spirochroman derivatives | 吉瑞工厂 | 2024-08-09 | — | — | CN | disclosed |
| EP-4408842-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2024-08-07 | — | — | EP | disclosed |
| EP-4404934-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118284606-A | Bicyclic amine derivatives as GABAA α5 receptor modulators | 吉瑞工厂 | 2024-07-02 | — | — | CN | disclosed |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240180204-A1 | PODS OF SUPPLEMENTS THAT DISSOLVE IN LIQUID SOLUTIONS AND MANUFACTURING METHODS THEREOF | REPS JAPAN Co., Ltd. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-11970479-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| CN-112805063-B | Bicyclic derivatives as modulators of the GABAA A5 receptor | 吉瑞工厂 | 2024-02-23 | — | — | CN | disclosed |
| US-20240043418-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-08 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| EP-3820869-B1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2023-08-30 | — | — | EP | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023141710-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-08-03 | — | — | WO | disclosed |
| CN-116261557-A | Cyclic cyanoketene derivatives as KEAP1 modulators | 默沙东有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4182299-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Merck Sharp & Dohme LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| WO-2023053015-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023049058-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-3644992-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4126858-A1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126859-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-C]PYRIDAZINE DERIVATIVES AS GABAA ALPHA5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2023-02-08 | — | — | EP | disclosed |
| EP-3684357-B1 | HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220396571-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3644990-B1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115348962-A | As GABA A Naphthyridines and pyrido [3,4-c ] of alpha 5 receptor modulators]Pyridazine derivatives | 吉瑞工厂 | 2022-11-15 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | AXOVANT SCIENCES GMBH (CH) | 2022-04-19 | — | — | US | disclosed |
| CN-109153649-B | Allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2022-04-19 | — | — | CN | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2021055576-A1 | COMBINATION OF MODAFINIL AND AN AMPAKINE FOR IMPROVING COGNITION | PURDUE PHARMA L.P. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055576-A1 | COMBINATION OF MODAFINIL AND AN AMPAKINE FOR IMPROVING COGNITION | PURDUE PHARMA L.P. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20190160059-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3436021-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RespireRx Pharmaceuticals Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20190030041-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | UNIV ALBERTA (CA) | 2019-01-31 | — | — | US | disclosed |
| EP-3311842-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | VeroScience LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018009256-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RESPIRERX PHARMACEUTICALS, INC. (US) | 2018-01-11 | — | — | WO | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160120873-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | UNIV ALBERTA (CA) | 2016-05-05 | — | — | US | disclosed |
| EP-3008167-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | VeroScience LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150011554-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2014201411-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | VEROSCIENCE LLC (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20120004219-A1 | Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8039468-B2 | administering to subject having respiratory depression a positive allosteric AMPA receptor modulator; selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20110218190-A1 | THERAPEUTIC USES OF AMPA RECEPTOR MODULATORS FOR TREATMENT OF MOTOR DYSFUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010054336-A2 | THERAPEUTIC USES OF AMPA RECEPTOR MODULATORS FOR TREATMENT OF MOTOR DYSFUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| EP-2061471-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | The Governors of the University of Alberta (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20080261962-A1 | administering to subject having respiratory depression a positive allosteric AMPA receptor modulator; selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| WO-2008025148-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2008-03-06 | — | — | WO | disclosed |
| EP-1428534-B1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | UNIV CALIFORNIA (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1428534-A1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | The Regents of the University of California (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6730677-B2 | TREATING MEMORY IMPAIRMENT; ENHANCE EXCITATORY SYNAPTIC ACTIVITY IN ORDER TO RESTORE AN IMBALANCE BETWEEN BRAIN SUBREGIONS, AS IN TREATMENT OF SCHIZOPHRENIA OR SCHIZOPHRENIFORM BEHAVIOR. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (44 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GRIA3 78/4885GRIA4 79/4885PKM 2848/4885 |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | GRIA3 104/4885GRIA4 133/4885PKM 3928/4885 |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | GABRA5, GABRA1, GABRB1 | GRIA3 94/4885GRIA4 118/4885PKM 1955/4885 |
| US-12194050-B2 | Thiadiazine derivatives | CHRNA5, CHRNA7, CHRNA1 | GRIA3 383/4885GRIA4 499/4885PKM 3088/4885 |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885PKM 1824/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GRIA3 4213/4885GRIA4 4210/4885PKM 1247/4885 |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | GRIA3 94/4885GRIA4 81/4885PKM 3110/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | GRIA3 38/4885GRIA4 37/4885PKM 1493/4885 |
| US-11970479-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM3, CHRM1 | GRIA3 64/4885GRIA4 39/4885PKM 1882/4885 |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | GRIA3 56/4885GRIA4 73/4885PKM 3795/4885 |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | GRIA3 128/4885GRIA4 53/4885PKM 2303/4885 |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | GRIA3 23/4885GRIA4 8/4885PKM 2869/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885PKM 1824/4885 |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | GPR3, OPRL1, ADGRF1 | GRIA3 235/4885GRIA4 841/4885PKM 4321/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GRIA3 4213/4885GRIA4 4210/4885PKM 1247/4885 |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | HTR2A, HTR5A, HTR1A | GRIA3 484/4885GRIA4 393/4885PKM 3388/4885 |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | BDNF, HTT, NTRK2 | GRIA3 90/4885GRIA4 200/4885PKM 4641/4885 |
| US-20220396571-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | GRIA3 80/4885GRIA4 73/4885PKM 2883/4885 |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | GRIA3 157/4885GRIA4 116/4885PKM 1334/4885 |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM3, CHRM5 | GRIA3 68/4885GRIA4 35/4885PKM 899/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | GRIA3 171/4885GRIA4 148/4885PKM 2588/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | GRIA3 11/4885GRIA4 4/4885PKM 2782/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GRIA3 4213/4885GRIA4 4210/4885PKM 1247/4885 |
| US-12064410-B2 | Compositions and methods for stimulating ventilatory and/or respiratory | CTH, SLC25A20, CRH | GRIA3 502/4885GRIA4 422/4885PKM 1011/4885 |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | GRIA3 63/4885GRIA4 62/4885PKM 3803/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GRIA3 4213/4885GRIA4 4210/4885PKM 1247/4885 |
| US-20240043418-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | GABRA5, GABRP, GABRA1 | GRIA3 44/4885GRIA4 52/4885PKM 805/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | GRIA3 24/4885GRIA4 14/4885PKM 1448/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | GRIA3 72/4885GRIA4 64/4885PKM 1751/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | GRIA3 42/4885GRIA4 53/4885PKM 1887/4885 |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | GRIA3 51/4885GRIA4 49/4885PKM 4410/4885 |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | GRIA3 94/4885GRIA4 44/4885PKM 2298/4885 |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | GRIA3 82/4885GRIA4 74/4885PKM 3212/4885 |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | GABRA5, GABRA1, GABRA3 | GRIA3 402/4885GRIA4 364/4885PKM 932/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIA3 26/4885GRIA4 22/4885PKM 299/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885PKM 1824/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | GRIA3 38/4885GRIA4 40/4885PKM 1729/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885PKM 1824/4885 |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | GSTM1, GSTO1, GSR | GRIA3 157/4885GRIA4 116/4885PKM 1334/4885 |
| US-20250064823-A1 | THIADIAZINE DERIVATIVES | CHRNA5, CHRNA7, CHRM5 | GRIA3 378/4885GRIA4 485/4885PKM 3129/4885 |
| US-20250051323-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | GABRA5, GABRB1, GABRA1 | GRIA3 103/4885GRIA4 120/4885PKM 1267/4885 |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | GRIA3 2118/4885GRIA4 3323/4885PKM 444/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | GRIA3 231/4885GRIA4 140/4885PKM 1481/4885 |
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRM1, CHRM5 | GRIA3 71/4885GRIA4 64/4885PKM 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.